

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is soliciting nominations for membership on the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC). The BSC, NCIPC consists of 18 experts in fields associated with surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence.

DATES: Nominations for membership on the BSC, NCIPC must be received no later than February 28, 2026. Packages received after this time will not be considered for the current membership cycle.

ADDRESSES: All nominations should be emailed (recommended) to ncipcbbsc@cdc.gov.

FOR FURTHER INFORMATION CONTACT:

Christopher R. Harper, Ph.D., Designated Federal Officer, Board of Scientific Counselors, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S-1069, Atlanta, GA 30341, Telephone (404) 718-8330. Email address: ncipcbbsc@cdc.gov.

SUPPLEMENTARY INFORMATION:

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC) objectives. Nominees will be selected based on expertise in the fields of pertinent disciplines involved in injury and violence prevention, including, but not limited to, epidemiology, statistics, trauma surgery, rehabilitation medicine, behavioral science/psychology, health economics, program evaluation, political science, law, criminology, informatics and other aspects of injury management. Federal employees will not be considered for membership. Members may be invited to serve for up to four-year terms. Selection of members is based on candidates' qualifications to contribute to the accomplishment of BSC, NCIPC objectives <https://www.cdc.gov/injury/bbsc/>.

Department of Health and Human Services (HHS) policy stipulates that committee membership be balanced in terms of points of view represented and the committee's function. Appointments shall be made without discrimination

on the basis of race, religion, color, national origin, age, disability, or sex. Nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Current participation on Federal workgroups or prior experience serving on a Federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. Committee members are Special Government Employees, requiring the filing of financial disclosure reports at the beginning and annually during their terms. The Centers for Disease Control and Prevention (CDC) reviews potential candidates for BSC, NCIPC membership each year and provides a slate of nominees for consideration to the Secretary of HHS for final selection. HHS notifies selected candidates of their appointment near the start of the term in September, or as soon as the HHS selection process is completed. Note that the need for different expertise varies from year to year and a candidate who is not selected in one year may be reconsidered in a subsequent year. Candidates should submit the following items:

- Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address).
- At least one letter of recommendation from person(s) not employed by HHS. Candidates may submit letter(s) from current HHS employees if they wish, but at least one letter must be submitted by a person not employed by an HHS agency (e.g., CDC, National Institutes of Health, Food and Drug Administration).

Nominations may be submitted by the candidate or by the person/organization recommending the candidate.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2025-23262 Filed 12-17-25; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single Source Unsolicited Grant To Fund University of Southern Denmark (SDU)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$1,600,000 over a five-year period, in response to an unsolicited proposal that has been submitted by University of Southern Denmark (SDU). The award will support a comparable study of the optimal timing and delivery of monovalent Hepatitis B vaccinations on newborns in Guinea-Bissau. Activities will include conducting a randomized controlled trial to assess the effects of neonatal Hepatitis B vaccination on early-life mortality, morbidity, and long-term developmental outcomes. The award is in response to an unsolicited proposal.

DATES: The period for this award will be January 5, 2026, through January 4, 2031.

FOR FURTHER INFORMATION CONTACT: Sam Beyda, Office of the Director, Office of the Chief of Staff, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, GA 30341, Telephone: (404) 404-639-7000, E-Mail: DirectorsIncoming@cdc.gov.

SUPPLEMENTARY INFORMATION: The proposed work being funded will support a single-blind, multi-center, phase IV randomized controlled trial enrolling over 14,000 neonates in Guinea-Bissau to evaluate the impact of neonatal monovalent Hepatitis B vaccination (HBV0) on all-cause mortality, severe morbidity, and long-term developmental outcomes. The study will also assess potential sex-differential effects of the vaccine. While the World Health Organization (WHO) recommends three vaccines at birth in low-income settings—Bacille Calmette Guérin (BCG), oral polio vaccine (OPV0), and HBV0—there is limited evidence on the broader health effects of HBV0. This study aims to fill that gap by rigorously evaluating the overall health impact of HBV0 in early life.

CDC performed an objective review of the proposed work and determined, in accordance with its process for reviewing unsolicited proposals that the

proposal has merit and that SDU is in a unique position to conduct this work, as it has extensive experience conducting vaccine trials in West Africa, established partnerships with local hospitals and health authorities in Guinea-Bissau, and a proven track record in neonatal and pediatric research in low-resource settings.

The award is being made non-competitively because there is no current, pending, or planned funding opportunity announcement under which this proposal could compete.

Summary of the Award

Recipient: University of Southern Denmark (SDU).

Purpose of the Award: The purpose of this award is to evaluate the effects of neonatal monovalent Hepatitis B vaccination (HBV0) on early-life mortality and morbidity, as well as long-term neurodevelopmental outcomes, through a randomized controlled trial in Guinea-Bissau. The findings will inform global immunization policy and practice, particularly regarding the broader health effects of HBV0, which remain less well understood compared to BCG and OPV0.

Amount of Award: \$1,600,000 in Federal Fiscal Year (FFY) 2026 funds, with the total estimated \$1,600,000 provided for the full five-year period of performance, subject to availability of funds.

Authority: This program is authorized under the Public Health Service Act, Sections 301(a) [42 U.S.C. 241], 307 (42 U.S.C. 242l), and 317(k)(2) [42 U.S.C. 247b], as amended.

Period of Performance: January 5, 2026, through January 4, 2031.

Dated: December 15, 2025.

Jamie Legier,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2025–23245 Filed 12–17–25; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for Office of Management and Budget Review; Personal Responsibility Education Program (PREP) Innovative Strategies (PREIS) Local Evaluation Support: Final Evaluation Report Template (New Collection)

AGENCY: Office of Planning, Research, and Evaluation, Administration for Children and Families, U.S. Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Administration for Children and Families (ACF) at the U.S. Department of Health and Human Services seeks approval of the Personal Responsibility Education Program (PREP) Innovative Strategies (PREIS) Local Evaluation Support: Final Evaluation Report Template for PREIS grantees. PREIS grant recipients are required to carry out local evaluations of their programs and submit a final evaluation report to ACF documenting their analyses and findings. This request includes guidance for grant recipients in the form of templates. Information will inform technical assistance (TA) to support grantees in developing and submitting the final reports to ACF to fulfill a grant requirement. We do not intend for this information to be used as the principal basis for public policy decisions.

DATES: *Comments due* January 20, 2026.

ADDRESSES: The public may view and comment on this information collection request at: https://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=202512-0970-005. You can also obtain copies of the proposed collection of information by emailing opreinfo@collection@acf.hhs.gov. Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The purpose of the current information collection request is to provide a standardized template and accompanying instructions to the 12 PREIS grant recipients carrying out impact evaluations. This template will help them document their evaluation's research questions, measures, study design, planned and actual implementation of the program, analytic methods, and findings. A structured final evaluation report template will facilitate grant recipients' efficient and effective reporting of evaluation findings. The completed reports will be reviewed by the PREP Local Evaluation Support (LES) team to determine whether they meet ACF's standards of rigor. The LES team will then develop recommendations for improvement and provide TA to support report development prior to final submission to ACF. While grantees are developing the reports, the PREP LES team will continue to provide support primarily by continuing to offer one-on-one TA calls with grant recipients.

The template will be used by grant recipients upon Office of Management and Budget approval until September 2026 (or until the end of their grant, if a no-cost extension is granted), which will allow them to submit draft versions of their final evaluation reports before revising and finalizing their reports by the end of their grant. Grant recipients will complete the PREIS Final Evaluation Report Template using the instructions which are included within each template section.

The information collected is meant to contribute to the body of knowledge on ACF programs. It is not intended to be used as the principal basis for a decision by a federal decision-maker and is not expected to meet the threshold of influential or highly influential scientific information.

Respondents: PREP PREIS Grant Recipients.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Average burden per response (in hours)	Total burden (in hours)	Annual burden (in hours)
PREIS Final Evaluation Report Template	12	1	40	480	240